PMID- 29332329
OWN - NLM
STAT- MEDLINE
DCOM- 20190731
LR  - 20221207
IS  - 1107-0625 (Print)
IS  - 1107-0625 (Linking)
VI  - 22
IP  - 6
DP  - 2017 Nov-Dec
TI  - Modified 3-week schedule of gemcitabine plus cisplatin for non-small cell lung 
      cancer treatment.
PG  - 1395-1403
AB  - PURPOSE: Gemcitabine-cisplatin combination is one of the most used schedules for 
      non small cell lung cancer (NSCLC). Aiming to enhance dose intensity and reduce 
      toxicity, the original 4-week schedule was modified or transformed into a 3-week 
      schedule. The purpose of this study was to report the efficacy and tolerability 
      of a modified 3-week regimen of gemcitabine-cisplatin. METHODS: Our patients were 
      treated with gemcitabine (1000 mg7sol;m(2)) on days 1, 8 and cisplatin on day 8 
      (75-100 mg/m(2)). The toxicity was recorded according to the NCIC criteria. 
      RESULTS: From October 2000 to December 2009 a consecutive series of 196 patients 
      with a median age of 62 years and III-IV stage NSCLC received 
      gemcitabine-cisplatin as induction therapy (76 patients) or palliative treatment 
      (120 patients). The median dose intensity was 89%. In relation to day 8 of 
      chemotherapy, 16.2% of the treatments were delayed due to hematologic toxicities. 
      Grade 3-4 anaemia, neutropenia and thrombocytopenia was reported in 3.5, 43.8 and 
      4.6%, respectively. Response rate (RR) and median overall survival (OS) were 74% 
      and 11 months in patients with locally advanced disease, and 46.7% and 9 months 
      in metastatic patients, respectively. CONCLUSIONS: In comparison with standard or 
      modified schedules of literature, our modified 3-week regimen of gemcitabine- 
      cisplatin demonstrated to be equally active, similar for dose intensity and well 
      tolerated, with better hematologic toxicity profile in terms of anaemia and 
      thrombocytopenia.
FAU - Veccia, Antonello
AU  - Veccia A
AD  - Medical Oncology Department, Santa Chiara Hospital, Largo Medaglie d'Oro, Trento, 
      Italy.
FAU - Murgia, Viviana
AU  - Murgia V
FAU - Dipasquale, Mariachiara
AU  - Dipasquale M
FAU - Caffo, Orazio
AU  - Caffo O
LA  - eng
PT  - Journal Article
PL  - Cyprus
TA  - J BUON
JT  - Journal of B.U.ON. : official journal of the Balkan Union of Oncology
JID - 100883428
RN  - 0 (Antineoplastic Agents)
RN  - 0W860991D6 (Deoxycytidine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - 0 (Gemcitabine)
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/pharmacology/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
MH  - Cisplatin/pharmacology/*therapeutic use
MH  - Deoxycytidine/*analogs & derivatives/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Gemcitabine
EDAT- 2018/01/15 06:00
MHDA- 2019/08/01 06:00
CRDT- 2018/01/15 06:00
PHST- 2018/01/15 06:00 [entrez]
PHST- 2018/01/15 06:00 [pubmed]
PHST- 2019/08/01 06:00 [medline]
PST - ppublish
SO  - J BUON. 2017 Nov-Dec;22(6):1395-1403.